MX362049B - Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica. - Google Patents

Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.

Info

Publication number
MX362049B
MX362049B MX2016016994A MX2016016994A MX362049B MX 362049 B MX362049 B MX 362049B MX 2016016994 A MX2016016994 A MX 2016016994A MX 2016016994 A MX2016016994 A MX 2016016994A MX 362049 B MX362049 B MX 362049B
Authority
MX
Mexico
Prior art keywords
htr
type
haematological malignancy
diagnosing
relates
Prior art date
Application number
MX2016016994A
Other languages
English (en)
Other versions
MX2016016994A (es
Inventor
Muñoz Risueño Ruth
Original Assignee
Inst De Recerca Contra La Leucemia Josep Carreras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Recerca Contra La Leucemia Josep Carreras filed Critical Inst De Recerca Contra La Leucemia Josep Carreras
Publication of MX2016016994A publication Critical patent/MX2016016994A/es
Publication of MX362049B publication Critical patent/MX362049B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un inhibidor del receptor de serotonina (5-HTR) seleccionado del grupo que consiste de un inhibidor del 5-HTR tipo 1 y un inhibidor del 5-HTR tipo 2 para uso en la prevención y/o tratamiento de una malignidad hematológica. Adicionalmente, la invención se refiere a métodos in vitro para la identificación o aislamiento de una célula maligna de una malignidad hematológica o para diagnosticar una malignidad hematológica con base en la detección de la expresión del 5-HTR tipo 1 y/o 5-HTR tipo 2. Además, la invención se refiere a métodos in vitro para determinar el pronóstico, para monitorear el efecto de una terapia o para diseñar una terapia personalizada en un sujeto que sufre de una malignidad hematológica con base en la determinación de los niveles del 5-HTR tipo 1 y/o 5-HTR tipo 2.
MX2016016994A 2014-06-27 2015-06-26 Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica. MX362049B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382249.2A EP2959904A1 (en) 2014-06-27 2014-06-27 Methods for treating, diagnosing and prognosing a haematological malignancy
PCT/EP2015/064571 WO2015197839A1 (en) 2014-06-27 2015-06-26 Methods for treating, diagnosing and prognosing a haematological malignancy

Publications (2)

Publication Number Publication Date
MX2016016994A MX2016016994A (es) 2017-06-09
MX362049B true MX362049B (es) 2019-01-04

Family

ID=51162662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016994A MX362049B (es) 2014-06-27 2015-06-26 Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.

Country Status (15)

Country Link
US (4) US10195207B2 (es)
EP (2) EP2959904A1 (es)
JP (2) JP2017526629A (es)
KR (1) KR102628235B1 (es)
CN (1) CN106471373B (es)
AU (2) AU2015279105B2 (es)
BR (1) BR112016029562B1 (es)
CA (1) CA2953272C (es)
DK (1) DK3160472T3 (es)
ES (1) ES2796056T3 (es)
IL (1) IL249579B (es)
MX (1) MX362049B (es)
RU (1) RU2727418C2 (es)
WO (1) WO2015197839A1 (es)
ZA (1) ZA201700080B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018022823A1 (en) * 2016-07-28 2018-02-01 Asieris Pharmaceutical Technologies Co., Ltd. Uses of dopamine beta-hydroxylase (dbh) inhibitors and serotonin receptor (5-ht) antagonists for the treatment of cancer
EP3348266A1 (en) * 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer
SG11202003886TA (en) * 2017-11-01 2020-05-28 Nat Univ Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
RU2020126518A (ru) 2018-01-18 2022-02-21 ЛЕУКОС БИОТЕК, Эс Эль Кристаллическая форма твердых частиц сокристалла апоморфин-пальмитиновая кислота
US11034751B1 (en) 2018-01-30 2021-06-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using serotonin receptor inhibitors
CN111257558B (zh) * 2020-01-19 2021-08-24 江苏省人民医院（南京医科大学第一附属医院） 基于机器学习的慢性淋巴细胞白血病肿瘤细胞识别方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
NL300886A (es) 1962-11-23
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
KR20040055311A (ko) * 2002-12-20 2004-06-26 주식회사 피앤아이 컨설팅 악성혈액종양 진단용 칩 및 이를 이용한 예후판단 시스템
WO2004072651A2 (en) * 2003-02-17 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)
WO2008098351A1 (en) * 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
WO2008146101A1 (en) 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases
RU2522493C2 (ru) * 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
WO2010135468A1 (en) * 2009-05-19 2010-11-25 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2015079439A1 (en) * 2013-11-26 2015-06-04 Technion Research And Development Foundation Limited Neuronal modulation
US20150197839A1 (en) * 2014-01-13 2015-07-16 Maria Celeste Rellamas Tria Forming conductive pattern using titania sol-gel

Also Published As

Publication number Publication date
US20220323456A1 (en) 2022-10-13
US20190343843A1 (en) 2019-11-14
RU2016147748A3 (es) 2019-02-13
MX2016016994A (es) 2017-06-09
DK3160472T3 (da) 2020-06-02
KR20170021253A (ko) 2017-02-27
US20210228593A1 (en) 2021-07-29
ZA201700080B (en) 2019-04-24
EP3160472B1 (en) 2020-03-11
EP3160472A1 (en) 2017-05-03
JP2017526629A (ja) 2017-09-14
CN106471373A (zh) 2017-03-01
BR112016029562B1 (pt) 2021-07-06
JP2020097608A (ja) 2020-06-25
KR102628235B1 (ko) 2024-01-22
ES2796056T3 (es) 2020-11-25
CN106471373B (zh) 2019-08-23
IL249579A0 (en) 2017-02-28
EP2959904A1 (en) 2015-12-30
IL249579B (en) 2019-03-31
US11337984B2 (en) 2022-05-24
CA2953272C (en) 2022-10-04
RU2016147748A (ru) 2018-08-03
AU2020200010A1 (en) 2020-01-30
AU2015279105A1 (en) 2016-12-15
JP6846551B2 (ja) 2021-03-24
US20170143735A1 (en) 2017-05-25
CA2953272A1 (en) 2015-12-30
US10195207B2 (en) 2019-02-05
WO2015197839A1 (en) 2015-12-30
AU2020200010B2 (en) 2020-11-19
AU2015279105B2 (en) 2019-10-03
RU2727418C2 (ru) 2020-07-21
BR112016029562A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
MX2016016994A (es) Metodos para tratar, diagnosticar y pronosticar una malignidad hematologica.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
MX2015000008A (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2017005126A (es) Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal.
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
MX2021006560A (es) Perfilado transcriptómico para prognosis de cáncer de mama.
MX2020002216A (es) Metodos y composiciones para detectar y tratar endometriosis.
MX2017015700A (es) Igfbp3 y sus usos.
MX2017004742A (es) Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
MX339340B (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
EP3693742A3 (en) Methods of detecting prostate cancer
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
SG10201806729VA (en) Novel assay to detect human periostin
PH12019500675A1 (en) Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
MX369175B (es) Métodos para detectar mutantes de akt resistentes a fármacos.
WO2014071218A3 (en) Biomarkers for breast cancer and methods of using same
WO2013132354A3 (en) Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer
MX371426B (es) Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos.
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
WO2016027029A3 (fr) Procédé pour déterminer le pronostic de survie d'un patient atteint d'un cancer du pancréas

Legal Events

Date Code Title Description
FG Grant or registration